Advertisement
Mini-Review| Volume 30, ISSUE 2, P149-155, April 2017

2016 Updates to US Medical Eligibility Criteria for Contraceptive Use and Selected Practice Recommendations for Contraceptive Use: Highlights for Adolescent Patients

Published:February 03, 2017DOI:https://doi.org/10.1016/j.jpag.2017.01.013

      Abstract

      The US Medical Eligibility Criteria for Contraceptive Use (MEC) and US Selected Practice Recommendations for Contraceptive Use (SPR) provide evidence-based guidance to safely provide contraception counseling and services. Both documents were updated in 2016 and are endorsed by the North American Society for Pediatric and Adolescent Gynecology. The purpose of this mini-review is to highlight updates to the US MEC and US SPR that are most relevant to health care providers of adolescents to support dissemination and implementation of these evidence-based best practices. This document is intended to highlight these changes and to complement, not replace, the detailed practice guidance within the US MEC and US SPR.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Kost K, Henshaw S: U.S. teenage pregnancies, births and abortions 2010: national and state trends by age, race and ethnicity. Available at: http://www.guttmacher.org/pubs/USTPtrends10.pdf. Accessed February 16, 2017.

        • Martin J.A.
        • Hamilton B.E.
        • Osterman M.J.
        • et al.
        Births: final data for 2014.
        Natl Vital Stat Rep. 2015; 64: 1
        • Lindberg L.
        • Santelli J.
        • Desai S.
        Understanding the decline in adolescent fertility in the United States, 2007–2012.
        J Adolesc Health. 2016; 59: 577
      2. Centers for Disease Control and Prevention: CDC winnable battles 2010-2015. Progress report 2014. Available at: https://www.cdc.gov/winnablebattles/targets/pdf/winnablebattles2010-2015_progressreport2014_.pdf. Accessed February 16, 2017.

        • Curtis K.M.
        • Tepper N.K.
        • Jatlaoui T.C.
        • et al.
        U.S. Medical Eligibility Criteria for Contraceptive Use.
        MMWR Recomm Rep. 2016; 65: 1
      3. World Health Organization: Medical Eligibility Criteria for Contraceptive Use, Fifth Edition 2015. Available at: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158_eng.pdf?ua=1. Accessed February 16, 2017

        • Curtis K.M.
        • Jatlaoui T.C.
        • Tepper N.C.
        • et al.
        U.S. Selected Practice Recommendations for Contraceptive Use.
        MMWR Recomm Rep. 2016; 65: 1
      4. World Health Organization: Selected Practice Recommendations for Contraceptive Use, Third Edition 2016. Available at: http://www.who.int/reproductivehealth/publications/family_planning/SPR-3/en/. Accessed February 16, 2017

        • Godfrey E.M.
        Helping clinicians prevent pregnancy among sexually active adolescents: U.S. medical eligibility criteria for contraceptive use and U.S. selected practice recommendations for contraceptive use.
        J Pediatr Adolesc Gynecol. 2015; 28: 209
        • Committee on Adolescence
        Contraception for adolescents.
        Pediatrics. 2014; 134: e1244
        • Ott M.
        • Sucato G.S.
        Committee on Adolescence: Technical report: contraception for adolescents.
        Pediatrics. 2014; 134: e1257
        • Gavin L.R.
        • Moskosky M.S.
        • Carter M.
        • et al.
        Providing Quality Family Planning Services: Recommendations of CDC and the U.S. Office of Population Affairs.
        MMWR Recomm Rep. 2014; 63: 1
        • Tocce K.M.
        • Sheeder J.L.
        • Teal S.B.
        Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference?.
        Am J Obstet Gynecol. 2012; 206: 481.e1
        • Tocce K.M.
        • Sheeder J.L.
        • Python J.
        • et al.
        Long-acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting.
        J Pediatr Adolesc Gynecol. 2012; 25: 59
        • Cohen R.
        • Sheeder J.L.
        • Arango N.
        • et al.
        Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices.
        Contraception. 2016; 93: 178
        • Curtis K.M.
        • Tepper N.K.
        • Jatlaoui T.C.
        • et al.
        U.S. medical eligibility criteria for contraceptive use, 2016.
        MMWR Recomm Rep. 2016; 65: 1
        • Marshall B.C.
        • Elbert A.
        • Petren K.
        • et al.
        Cystic Fibrosis Foundation Patient Registry 2014 Annual Data Report.
        Cystic Fibrosis Foundation, Bethesda, MD2014
        • Whiteman M.K.
        • Oduyebo T.
        • Zapata L.B.
        • et al.
        Contraceptive safety among women with cystic fibrosis: a systematic review.
        Contraception. 2016; 93: 3
        • Ahmad A.
        • Ahmed A.
        • Patrizio P.
        Cystic fibrosis and fertility.
        Curr Opin Obstet Gynecol. 2013; 25: 167
      5. Orkambi (lumacaftor/ivacaftor) tablets, for oral use [highlights of prescribing information]. Available at: http://pi.vrtx.com/files/uspi_lumacaftor_ivacaftor.pdf. Accessed February 16, 2017.

        • Tepper N.K.
        • Whiteman M.K.
        • Zapata L.B.
        • et al.
        Safety of hormonal contraceptives among women with migraine: a systematic review.
        Contraception. 2016; 94: 630
        • Brodsky J.R.
        • Cusick B.A.
        • Zhou G.
        • et al.
        The International Classification of Headache Disorders, 3rd edition (beta version).
        Cephalalgia. 2015; 35: 137
        • Kurth T.
        The association of migraine with ischemic stroke.
        Curr Neurol Neurosci Rep. 2010; 10: 133
        • Jatlaoui T.C.
        • Simmons K.B.
        • Curtis K.M.
        The safety of intrauterine contraception initiation among women with current asymptomatic cervical infections or at increased risk of sexually transmitted infections.
        Contraception. 2016; 94: 701
        • Workowski K.A.
        • Bolan G.A.
        Sexually transmitted diseases treatment guidelines, 2015.
        MMWR Recomm Reports. 2015; 64: 1
        • Mohllajee A.P.
        • Curtis K.M.
        • Peterson H.B.
        Does insertion and use of an intrauterine device increase the risk of pelvic inflammatory disease among women with sexually transmitted infection? A systematic review.
        Contraception. 2006; 73: 145
        • Wu J.P.
        • Pickle S.
        Extended use of the intrauterine device: a literature review and recommendations for clinical practice.
        Contraception. 2014; 89: 495
        • Trussell J.
        Contraceptive failure in the United States.
        Contraception. 2011; 83: 397
        • Rosenstock J.R.
        • Peipert J.F.
        • Madden T.
        • et al.
        Continuation of reversible contraception in teenagers and young women.
        Obstet Gynecol. 2012; 120: 1298
      6. Mirena (levonorgestrel-releasing intrauterine system) [highlights of prescribing information]. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Mirena_PI.pdf. Accessed September 26, 2016.

      7. Liletta (levonorgestrel-releasing intrauterine system) [highlights of prescribing information]. Available at: http://www.allergan.com/assets/pdf/liletta-shi-pi_ppi_052016. Accessed September 26, 2016.

      8. Skyla (levonorgestrel-releasing intrauterine system) [highlights of prescribing information]. Available at: http://labeling.bayerhealthcare.com/html/products/pi/Skyla_PI.pdf. Accessed September 26, 2016.

        • Zapata L.B.
        • Jatlaoui T.C.
        • Marchbanks P.A.
        • et al.
        Medications to ease intrauterine device insertion: a systematic review.
        Contraception. 2016; 94: 739
        • Lopez L.M.
        • Bernholc A.
        • Zeng Y.
        • et al.
        Interventions for pain with intrauterine device insertion.
        Cochrane Database Syst Rev. 2015; 7: CD007373
        • Bahamondes M.V.
        • Espejo-Arce X.
        • Bahamondes L.
        Effect of vaginal administration of misoprostol before intrauterine contraceptive insertion following previous insertion failure: a double blind RCT.
        Hum Reprod. 2015; 30: 1861
        • Cirik D.
        • Taskin E.
        • Tuglu A.
        • et al.
        Paracervical block with 1% lidocaine for pain control during intrauterine device insertion: a prospective, single-blinded, controlled study.
        Int J Reprod Contraception Obstet Gynecol. 2013; 2: 263
        • Mody S.K.
        • Kiley J.
        • Rademaker A.
        • et al.
        Pain control for intrauterine device insertion: a randomized trial of 1% lidocaine paracervical block.
        Contraception. 2012; 86: 704
      9. Nexplanon (etonogestrel implant) [highlights of prescribing information]. Available at: http://www.merck.com/product/usa/pi_circulars/n/nexplanon/nexplanon_pi.pdf. Accessed September 25, 2016.

        • McNicholas C.
        • Maddipati R.
        • Zhao Q.
        • et al.
        Use of the etonogestrel implant and levonorgestrel intrauterine device beyond the U.S. Food and Drug Administration– approved duration.
        Obstet Gynecol. 2015; 125: 599
        • Kissner D.
        Role of progestational agents in the treatment of undernourished patients with cystic fibrosis.
        Pediatr Pulmonol. 2000; 29: 242
        • Plant B.J.
        • Goss C.H.
        • Tonelli M.R.
        • et al.
        Contraceptive practices in women with cystic fibrosis.
        J Cyst Fibros. 2008; 7: 412
        • Winner B.
        • Peipert J.F.
        • Zhao Q.
        • et al.
        Effectiveness of long-acting reversible contraception.
        N Engl J Med. 2012; 366: 1998
        • Gillum L.A.
        • Mamidipudi S.K.
        • Johnston S.C.
        Ischemic stroke risk with oral contraceptives: a meta-analysis.
        JAMA. 2000; 284: 72
        • Xu Z.
        • Li Y.
        • Tang S.
        • et al.
        Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies.
        Thromb Res. 2015; 136: 52
        • Schurks M.
        • Rist P.M.
        • Bigal M.E.
        • et al.
        Migraine and cardiovascular disease: systematic review and meta-analysis.
        BMJ. 2009; 339: b3914
        • Spector J.T.
        • Kahn S.R.
        • Jones M.R.
        • et al.
        Migraine headache and ischemic stroke risk: an updated meta-analysis.
        Am J Med. 2010; 123: 612
        • Raymond E.
        • Pradhan A.
        ACOG Practice Bulletin No. 112: emergency contraception.
        Obstet Gynecol. 2010; 115: 1100
        • Glasier A.F.
        • Cameron S.T.
        • Fine P.M.
        • et al.
        Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysis.
        Lancet. 2010; 375: 555
        • Turok D.K.
        • Jacobson J.C.
        • Dermish A.I.
        • et al.
        Emergency contraception with a copper IUD or oral levonorgestrel: an observational study of 1-year pregnancy rates.
        Contraception. 2014; 89: 222
        • Cleland K.
        • Zhu H.
        • Goldstuck N.
        • et al.
        The efficacy of intrauterine devices for emergency contraception: a systematic review of 35 years of experience.
        Hum Reprod. 2012; 27: 1994
        • Cheng L.
        • Che Y.
        • Gulmezoglu A.M.
        Interventions for emergency contraception.
        Cochrane Database Syst Rev. 2012; 8: CD001324
        • Brache V.
        • Cochon L.
        • Duijkers I.J.M.
        • et al.
        A prospective, randomized, pharmacodynamic study of quick-starting a desogestrel progestin-only pill following ulipristal acetate for emergency contraception.
        Hum Reprod. 2015; 30: 2785
        • Horton L.G.
        • Folger S.G.
        • Berry-Bibee E.
        • et al.
        Research gaps from evidence-based contraception guidance: the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 and the U.S. Selected Practice Recommendations for Contraceptive Use, 2016.
        Contraception. 2016; 94: 582
        • Pagano H.P.
        • Zapata L.B.
        • Berry-Bibee E.N.
        • et al.
        Safety of hormonal contraception and intrauterine devices among women with depressive and bipolar disorders: a systematic review.
        Contraception. 2016; 94: 641
        • Skovlund C.W.
        • Mørch L.S.
        • Kessing L.V.
        • et al.
        Association of hormonal contraception with depression.
        JAMA Psychiatry. 2016; 73: 1154
        • Potter J.
        • Rubin S.E.
        • Sherman P.
        Fear of intrauterine contraception among adolescents in New York City.
        Contraception. 2014; 89: 446
        • Brown M.K.
        • Auerswald C.
        • Eyre S.L.
        • et al.
        Identifying counseling needs of nulliparous adolescent intrauterine contraceptive users: a qualitative approach.
        J Adolesc Health. 2013; 52: 293
        • Berlan E.
        • Mizraji K.
        • Bonny A.E.
        Twelve-month discontinuation of etonogestrel implant in an outpatient pediatric setting.
        Contraception. 2016; 94: 81